Brief: RenovoRx Phase III Open Label TIGeR-PaC Interim Analysis Shows Promising Data
08/03/2023 17:44
March 8 (Reuters) - RenovoRx Inc RNXT.O :
* RENOVORX PHASE III OPEN LABEL TIGER-PAC INTERIM ANALYSIS
SHOWS
PROMISING DATA THAT SUPPORT CONTINUED CLINICAL INVESTIGATION OF
RENOVOGEMTM AS A TREATMENT OPTION FOR LOCALLY ADVANCED
PANCREATIC CANCER
Source text for Eikon: ID:nBwn2fpVa
Further company coverage: RNXT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on RenovoRx
See all newsBrief: RenovoRx Gets FDA Orphan Drug Designation For Oxaliplatin To Treat Pancreatic Cancer
RenovoRx Q1 revenue rises as number of active cancer centers increase
RenovoRx 2025 net loss widens on higher operating expenses
Brief: RenovoRx FY Net Income USD -11.168 Million
U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi Technologies